Our treatment, administered via rectal enema, aims to regenerate the enteric nervous system that is otherwise missing in the colon of patients with Hirschsprung disease, typically young children. This treatment is also designed to improve overall intestinal function of these children, bearing hope to improve their quality of life.
A pioneering biotechnology company
Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company developing an innovative treatment for Hirschsprung disease. Nicolas Pilon, a rare diseases expert, and Rodolphe Soret, a neuro-gastroenterology specialist, combined their expertise to develop a potentially curative treatment for Hirschsprung disease. With Maxime Ranger, serial entrepreneur, and various experts in medicine, gastroenterology, and rare disease clinical trials, the company is committed to bringing this treatment into clinical practice.
more information
News
See all news +08 May 2024
Neurenati Therapeutics Strengthens Its Board of Directors With the Appointment of Dr. Marielle Cohard-Radice18 April 2024
Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ With the Support of Impulsion PME29 February 2024
Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease29 February 2024
Innovative treatment for rare Hirschsprung disease